Drugs / VRC-MARDNA025-00-VP
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00997607 | Feb 2010 → Apr 2012 | Ebola hemorrhagic fever, Marburg hemorrhagic fever | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT00605514 | Jan 2008 → Jun 2010 | Ebola hemorrhagic fever, Marburg hemorrhagic fever | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VRC-MARDNA025-00-VP | “4 mg of Marburg DNA plasmid vaccine, VRC-MARDNA025-00-VP, delivered via intramuscular injection on Weeks 0, 4, and 8” NCT00997607 ↗ |
| Known as | Marburg DNA | “VRC-MARDNA025-00-VP (Marburg DNA) is composed of one closed-circular DNA plasmid encoding for the glycoprotein (GP) from the Angola strain of Marburg.” NCT00605514 ↗ |
| Route | Intramuscular | “Each DNA vaccination will be 1 mL of vaccine administered intramuscularly (IM) into the deltoid muscle” NCT00605514 ↗ |